Literature DB >> 1464627

Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance.

T E Willnow1, J L Goldstein, K Orth, M S Brown, J Herz.   

Abstract

The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and gp330, two members of the low density lipoprotein receptor gene family, share a multitude of cysteine-rich repeats. LRP has been shown to act as an endocytosis-mediating receptor for several ligands, including protease-antiprotease complexes and plasma lipoproteins. The former include alpha 2-macroglobulin-protease complexes and plasminogen activator inhibitor-activator complexes. The latter include chylomicron remnant-like particles designated beta-very low density lipoproteins (beta-VLDL) complexed with apoprotein E or lipoprotein lipase. The binding specificity of gp330 is unknown. In the current studies we show that gp330 from rat kidney membranes binds several of these ligands on nitrocellulose blots. We also show that both LRP and gp330 bind an additional ligand, bovine lactoferrin, which is known to inhibit the hepatic clearance of chylomicron remnants. Lactoferrin blocked the LRP-dependent stimulation of cholesteryl ester synthesis in cultured human fibroblasts elicited by apoprotein E-beta-VLDL or lipoprotein lipase-beta-VLDL complexes. Cross-competition experiments in fibroblasts showed that the multiple ligands recognize at least three distinct, but partially overlapping sites on the LRP molecule. Binding of all ligands to LRP and gp330 was inhibited by the 39-kDa protein, which co-purifies with the two receptors, suggesting that the 39-kDa protein is a universal regulator of ligand binding to both receptors. The correlation of the inhibitory effects of lactoferrin in vivo and in vitro support the notion that LRP functions as a chylomicron remnant receptor in liver. LRP and gp330 share a multiplicity of binding sites, and both may function as endocytosis-mediating receptors for a large number of ligands in different organs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464627

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.

Authors:  M Tolar; M A Marques; J A Harmony; K A Crutcher
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Localization of basic residues required for receptor binding to the single alpha-helix of the receptor binding domain of human alpha2-macroglobulin.

Authors:  W Huang; K Dolmer; X Liao; P G Gettins
Journal:  Protein Sci       Date:  1998-12       Impact factor: 6.725

3.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

4.  Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique.

Authors:  V N Bochkov; V A Tkachuk; M P Philippova; D V Stambolsky; F R Bühler; T J Resink
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

5.  The Drosophila yolkless gene encodes a vitellogenin receptor belonging to the low density lipoprotein receptor superfamily.

Authors:  C P Schonbaum; S Lee; A P Mahowald
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin.

Authors:  S K Moestrup; I Schousboe; C Jacobsen; J R Leheste; E I Christensen; T E Willnow
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.

Authors:  S Ishibashi; J Herz; N Maeda; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

Authors:  S K Moestrup; S Cui; H Vorum; C Bregengård; S E Bjørn; K Norris; J Gliemann; E I Christensen
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

9.  Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex.

Authors:  R A Orlando; M G Farquhar
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

10.  The LDL receptor and LRP are receptors for beta VLDL on pigeon monocyte-derived macrophages.

Authors:  N L Jones; M Gupta; J C Lewis
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.